secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2025-02-20T23:59:59+00:00
Accession:  0000950170-25-023729
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen sells China ops to AstraZeneca for ~$160M; cash runway to 2027
-----------------------------------------------------------------------

- Purchase price: $85M enterprise value plus net China cash (~$75M) for total ~$160M.
- Transaction expected to close by mid-2025, subject to China regulatory approval.
- Proceeds will repay ~$80M term loan to Morgan Stanley Tactical Value; cash runway extended into 2027.
- Upon close, AstraZeneca gets full roxadustat rights in China; FibroGen retains U.S. and ex-AstraZeneca markets.
- Senior VP China Operations Christine Chung will depart upon closing; Phase 2 trial of FG-3246 in mCRPC expected 2Q 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017025023729/0000950170-25-023729-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017025023729/fgen-20250219.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-023729

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer